Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Pharmacoepidemiology and Drug Safety|January 26, 2019
Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research NetworkAndrew D Wiese, Christianne L Roumie, John B Buse, et al.
American Heart Journal|May 25, 2024
Framework of the strengths and challenges of clinically integrated trials: An expert panel reportAnthony E Peters, W Schuyler Jones, Brian Anderson, et al.
Learning Health Systems|October 20, 2022
Training the next generation of learning health system scientistsPaula M Lozano, Meghan Lane-Fall, Patricia D Franklin, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 22, 2023
Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ)Susanna Naggie, Aaron Milstone, Mario Castro, et al.
Diabetes Care|September 15, 2023
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE TrialDennis I Narcisse, Hwasoon Kim, Lisa M Wruck, et al.
JAMA Cardiology|October 4, 2023
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical TrialAmber Sleem, Mark B Effron, Amanda Stebbins, et al.
Circulation. Heart Failure|February 12, 2017
Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department: GUIDED-HF (Get With the Guidelines in Emergency Department Patients With Heart Failure)Gregory J Fermann, Phillip D Levy, Peter Pang, et al.
American Heart Journal|June 8, 2023
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLEKamal Gupta, Harsh Mehta, Hwasoon Kim, et al.
American Heart Journal|December 28, 2025
Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist:PRECIDENTD pragmatic randomized trialDeborah J Wexler, Lindsay S Mayberry, Lyndsay A Nelson, et al.
Contemporary Clinical Trials|July 27, 2025
Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trialDennis I Narcisse, Jeff Whittle, Grace M Rhodes, et al.
Pageof 20